US expands COVID reinforcements to all adults, final hurdle ahead

US expands COVID reinforcements to all adults, final hurdle ahead

Washington — US regulators on Friday opened booster COVID-19 footage to all adults, expanding the government’s drive to boost protections and anticipate rising coronavirus cases that could worsen with the holidays.

Pfizer and Moderna announced the FDA’s decision after at least 10 states began making the boosters available to all adults. The latest measure simplifies what has hitherto been a confusing list of who is eligible by allowing anyone 18 and older to choose a booster for either company six months after their last dose — regardless of which vaccine they got first.

But there’s one more step: The Centers for Disease Control and Prevention must agree to expand Pfizer and Moderna boosters to include even healthy young adults. Its scientific advisors are scheduled to discuss later on Friday.

If the CDC approves, tens of millions of Americans could get three doses of protection before the new year. Anyone who has received a single dose of the Johnson & Johnson vaccine can already get a booster dose.


The three COVID-19 vaccines used in the United States still provide strong protection against severe illness including hospitalization and death, but the protection against infection can wane over time. Previously, the government had authorized boosters of the Pfizer and BioNTech vaccine, as well as the similar Moderna vaccine, only for vulnerable groups including older Americans and people with chronic health problems.

The move to expand comes as new COVID-19 cases have risen steadily over the past two weeks, especially in states where cold weather is driving people indoors.

These troubling trends sparked some states, and they didn’t wait for federal officials to act. Utah and Massachusetts were the latest states to announce last week that they are opening reinforcements to all adults.

Reinforcements for all were the original goal of the Biden administration. But in September, a panel of FDA advisors voted overwhelmingly against that idea based on the vaccines’ continued effectiveness in most age groups. Instead, they approved an additional dose of Pfizer for the most vulnerable groups only.


Since then, administration officials, including Dr. Anthony Fauci, have continued to make the case for broader use of boosters, noting that even milder infections in young adults can cause “prolonged Covid” and other complications.

“I don’t know of any other vaccine as we’re only concerned about keeping people out of the hospital,” Fauci said at a news briefing on Wednesday.

Last week, Pfizer and its German partner BioNTech presented new data to demonstrate that broader boosters can help curb infection at a critical period.

“We have absolutely no chance in the current situation of controlling the epidemic without providing reinforcements to everyone,” BioNTech CEO Ugur Sahin told reporters during a visit to Washington last week.

The companies studied 10,000 adults of all ages and found that the booster restored protection against symptomatic infections to about 95% even while the highly contagious delta variant was increasing. It’s too soon to know if this high level of protection will last longer after the third shot than after the second, something Shaheen said the companies will follow carefully.


In support of this evidence, Britain released factual data this week showing the same leap in protection once it began offering boosters to middle-aged and older adults. Israel credits boosters on a large scale for helping to stave off another wave of the virus in that country.

More than 195 million Americans have been fully vaccinated, defined as having received two doses of Pfizer, Moderna or a single dose of Johnson & Johnson. More than 30 million have already received a booster dose.

Prior to the expansion, people who received the Pfizer or Moderna vaccines were eligible for a third dose if they were elderly or at risk of contracting COVID-19 due to health problems, their jobs or their living conditions. Because the J&J injection has not been shown to be as effective as its two-dose competitors, any J&J recipient can get a booster dose after at least two months.

But people who don’t meet the criteria often score an extra shot because many vaccine sites don’t verify qualifications.


The FDA has previously ruled that people who get a booster dose can get a different brand of the vaccine they initially received.

Some experts worry that all the attention to boosters could harm efforts to reach the 60 million Americans who are eligible to be vaccinated but who do not get vaccinated. There is also growing concern that rich countries provide boosters on a large scale when poor countries cannot vaccinate more than a small part of their population.

“In terms of priority No. 1 to reduce transmission in this country and around the world, that remains to get people the first series of vaccines,” said Dr. David Dowdy of the Johns Hopkins Bloomberg School of Public Health.


The Associated Press’s Department of Health and Science receives support from the Howard Hughes Medical Institute’s Division of Science Education. AP is solely responsible for all content.

Copyright 2021 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.

Leave a Reply

Your email address will not be published. Required fields are marked *